Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2026

Conditions

Colorectal Cancer

Interventions

DRUG

Camrelizumab

Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.

Trial Locations (1)

RECRUITING

Department of Colorectal Surgery, Affiliated Jinhua Hosptial, Zhejiang University, Jinhua

All Listed Sponsors

lead

yue junhan

OTHER